Viking Therapeutics, Inc. - Common Stock (VKTX)
CUSIP: 92686J106
Q2 2017 13F Holders as of 30 Jun 2017
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 113,177,462
- Total 13F shares
- 1,568,425
- Share change
- +798,824
- Total reported value
- $1,692,000
- Price per share
- $1.08
- Number of holders
- 11
- Value change
- +$856,257
- Number of buys
- 5
- Number of sells
- 3
Quarterly Holders Quick Answers
What is CUSIP 92686J106?
CUSIP 92686J106 identifies VKTX - Viking Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 92686J106:
Top shareholders of VKTX - Viking Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
|
Company |
0.29%
|
330,689
|
$483,000 | — | 31 Mar 2017 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.23%
|
265,800
|
$388,000 | — | 31 Mar 2017 | |
| SHEPHERD KAPLAN KROCHUK, LLC |
13F
|
Company |
0.09%
|
103,978
|
$152,000 | — | 31 Mar 2017 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.03%
|
31,264
|
$45,000 | — | 31 Mar 2017 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.01%
|
16,962
|
$25,000 | — | 31 Mar 2017 | |
| Acrospire Investment Management LLC |
13F
|
Company |
0.01%
|
12,642
|
$18,000 | — | 31 Mar 2017 | |
| UBS Group AG |
13F
|
Company |
0%
|
4,506
|
$7,000 | — | 31 Mar 2017 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0%
|
1,807
|
$3,000 | — | 31 Mar 2017 | |
| REILLY FINANCIAL ADVISORS, LLC |
13F
|
Company |
0%
|
1,250
|
$2,000 | — | 31 Mar 2017 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0%
|
703
|
$1,000 | — | 31 Mar 2017 | |
| Advisor Group, Inc. |
13F
|
Company |
0%
|
500
|
$1,000 | — | 31 Mar 2017 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
398
|
$1,000 | — | 31 Mar 2017 |
Institutional Holders of Viking Therapeutics, Inc. - Common Stock (VKTX) as of Q2 2017
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2017 vs Q1 2017 Across Filers
| Investor | Q1 2017 Shares | Q2 2017 Shares | Share Diff | Share Chg % | Q1 2017 Value $ | Q2 2017 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.